ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apazunersen sodium

Also written as “GTX-102”, “GTX-102 medium dose fast Period 1 and Period 2” and “GTX-102 medium dose slow Period 1 and Period 2”.

Its studies are mostly in Angelman Syndrome · Ataxia Telangiectasia, led by 2 companies.

Drug pageApazunersen sodium: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 10, 20245 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ultragenyx Pharmaceuticalits history only40 open or runningphase 3since May 10, 2024Jan 31, 2020none ahead
Grace Therapeutics10 open or runningphase 1since Aug 31, 2022Aug 31, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Grace Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2022First study: phase 1 study in Ataxia TelangiectasiaFirst studyNCT05531890 · 48 enrolled · Canada

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Grace Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05531890Ataxia Telangiectasia · Canada1UNKNOWNNov 24, 202248

How it is read

Names in the registry

  • “GTX-102”, 4 entries
  • “GTX-102 medium dose fast Period 1 and Period 2”, 1 entry
  • “GTX-102 medium dose slow Period 1 and Period 2”, 1 entry
  • “GTX-102 high dose fast Period 1 and Period 2”, 1 entry
  • “GTX-102 low dose fast Period 1 and Period 2”, 1 entry

Codes read as this program: GTX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.